Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Albumin infusion in cirrhosis patients with hepatic encephalopathy
2014-004809-33Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jan 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of albumin (human) in hepatic encephalopathy (HE) and Cirrhosis, sponsored by Vall d'Hebron Research Institute. Primary endpoint: Survival at 90 days. Started Jan 2015; status: completed.
02
Drugs
albumin (human)
03
Conditions
hepatic encephalopathy (HE)Cirrhosis
Beyond the preview
Go deeper on 2014-004809-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004809-33.